English

Akcea Therapeutics, Inc.

EDGAR

AKCA Quarterly report (10-Q) · filed 2020-08-05

64 filing records in this dataset, filed from 2016-01-04 to 2020-08-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

22.4 million USD

2020 Q2 · USD

Exact inputs and evidence

Revenue: 22377000 USD Source

Operating margin

-228.32%

2020 Q2 · %

Exact inputs and evidence

Operating Income: -51091000 USD Source
Revenue: 22377000 USD Source

Operating cash flow

-33.4 million USD

2020 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -77500000 USD Source
Operating Cash Flow: -44105000 USD Source

Free cash flow

-33.7 million USD

2020 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -77500000 USD Source
Operating Cash Flow: -44105000 USD Source
Capital Expenditure: 558000 USD Source
Capital Expenditure: 209000 USD Source

Cash and cash equivalents: 136 million USD 2020-06-30 Source
Exact value

135744000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 102 million shares 2020-06-30 Source
Exact value

101509223 shares

Reported share-count change

9.24% · 8.59 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

92921173 shares · 2019-06-30· Source
101509223 shares · 2020-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-08-05.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2019-12-31
Operating income: 4 of 11 periods available· newest 2019-12-31
Net income: 4 of 11 periods available· newest 2019-12-31
Operating cash flow: 4 of 11 periods available· newest 2019-12-31
Capital expenditure: 4 of 11 periods available· newest 2019-12-31
Total assets: 3 of 11 periods available· newest 2019-12-31
Total liabilities: 3 of 11 periods available· newest 2019-12-31
Current assets: 3 of 11 periods available· newest 2019-12-31
Current liabilities: 3 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+653.1%

Prior period

USD 64.87 million

2018-01-01 – 2018-12-31
Current period

USD 488.54 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

488543000 − 64867000 = 423676000 USD

64867000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
488543000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Year-over-year change in Revenue: 423676000 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 488543000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#236765 Filing: 000156459020008119 Input fundies:Revenue: 64867000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#236995 Filing: 000156459020008119
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 266.59 million

Prior period

−USD 225.82 million

2018-01-01 – 2018-12-31
Current period

USD 40.77 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

40772000 − -225821000 = 266593000 USD

-225821000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
40772000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Year-over-year change in Net income: 266593000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 40772000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#245676 Filing: 000156459020008119 Input fundies:NetIncome: -225821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#245829 Filing: 000156459020008119
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 426.71 million

Prior period

−USD 202.89 million

2018-01-01 – 2018-12-31
Current period

USD 223.83 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

223825000 − -202888000 = 426713000 USD

-202888000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
223825000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Year-over-year change in Operating cash flow: 426713000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 223825000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297766 Filing: 000156459020008119 Input fundies:OperatingCashFlow: -202888000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297978 Filing: 000156459020008119
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+42.6%

Prior period

USD 1.12 million

2018-01-01 – 2018-12-31
Current period

USD 1.6 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

1596000 − 1119000 = 477000 USD

1119000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
1596000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Year-over-year change in Capital expenditure: 477000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1596000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299782 Filing: 000156459020008119 Input fundies:CapitalExpenditure: 1119000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299992 Filing: 000156459020008119
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 488.54 million 100% of revenue
Operating costs Derived USD 450.47 million 92% of revenue
Operating income USD 38.07 million 7.8% of revenue
Tax, interest and other Derived −USD 2.7 million −0.6% of revenue
Net income USD 40.77 million 8.3% of revenue

Cash

Operating cash flow USD 223.83 million 46% of revenue
Capital expenditure USD 1.6 million 0.3% of revenue
Free cash flow Derived USD 222.23 million 45% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Operating loss: operating costs were 378% of revenue.
2018 Operating loss: operating costs were 456% of revenue.
2019 Net income was higher than operating income, so the split is not drawn.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	83512000 Derived	-83512000	-295000 Derived	-83217000	-55540000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -83512000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -83217000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -55361000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 179000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	43401000	163871000 Derived	-120470000	1089000 Derived	-121559000	-36199000 Derived	Source 2017-01-01 – 2017-12-31: 43401000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -120470000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -121559000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -36190000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 9000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	64867000	295683000 Derived	-230816000	-4995000 Derived	-225821000	-204007000 Derived	Source 2018-01-01 – 2018-12-31: 64867000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -230816000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -225821000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -202888000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1119000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	488543000	450469000 Derived	38074000	-2698000 Derived	40772000	222229000 Derived	Source 2019-01-01 – 2019-12-31: 488543000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 38074000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 40772000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 223825000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1596000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 488.5M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	43401000	Revenue: 43401000 Open source
20182018-12-31	Revenue	64867000	Revenue: 64867000 Open source
20192019-12-31	Revenue	488543000	Revenue: 488543000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

653.1% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 43401000 Open source Revenue: 0 Open source
20182018-12-31	Year over year	49.5%	Revenue: 64867000 Open source Revenue: 43401000 Open source
20192019-12-31	Year over year	653.1%	Revenue: 488543000 Open source Revenue: 64867000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 7.8% 2019

Net margin 8.3% 2019

Free cash flow margin 45.5% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -83512000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	-277.6%	Operating Income: -120470000 Open source Revenue: 43401000 Open source
20182018-12-31	Operating margin	-355.8%	Operating Income: -230816000 Open source Revenue: 64867000 Open source
20192019-12-31	Operating margin	7.8%	Operating Income: 38074000 Open source Revenue: 488543000 Open source
20162016-12-31	Net margin	Not reported	Net Income: -83217000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	-280.1%	Net Income: -121559000 Open source Revenue: 43401000 Open source
20182018-12-31	Net margin	-348.1%	Net Income: -225821000 Open source Revenue: 64867000 Open source
20192019-12-31	Net margin	8.3%	Net Income: 40772000 Open source Revenue: 488543000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -55361000 Open source Capital Expenditure: 179000 Open source
20172017-12-31	Free cash flow margin	-83.4%	Revenue: 43401000 Open source Operating Cash Flow: -36190000 Open source Capital Expenditure: 9000 Open source
20182018-12-31	Free cash flow margin	-314.5%	Revenue: 64867000 Open source Operating Cash Flow: -202888000 Open source Capital Expenditure: 1119000 Open source
20192019-12-31	Free cash flow margin	45.5%	Revenue: 488543000 Open source Operating Cash Flow: 223825000 Open source Capital Expenditure: 1596000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 223.8M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-55361000	Operating Cash Flow: -55361000 Open source
20172017-12-31	Operating cash flow	-36190000	Operating Cash Flow: -36190000 Open source
20182018-12-31	Operating cash flow	-202888000	Operating Cash Flow: -202888000 Open source
20192019-12-31	Operating cash flow	223825000	Operating Cash Flow: 223825000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 222.2M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-55540000	Operating Cash Flow: -55361000 Open source Capital Expenditure: 179000 Open source
20172017-12-31	Free cash flow	-36199000	Operating Cash Flow: -36190000 Open source Capital Expenditure: 9000 Open source
20182018-12-31	Free cash flow	-204007000	Operating Cash Flow: -202888000 Open source Capital Expenditure: 1119000 Open source
20192019-12-31	Free cash flow	222229000	Operating Cash Flow: 223825000 Open source Capital Expenditure: 1596000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

9.4% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	37.6%	Total Liabilities: 100979000 Open source Total Assets: 268804000 Open source
20182018-12-31	Liabilities / assets	24.2%	Total Liabilities: 88537000 Open source Total Assets: 365261000 Open source
20192019-12-31	Liabilities / assets	9.4%	Total Liabilities: 56246000 Open source Total Assets: 599250000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

11.83× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	3.02×	Current Assets: 266845000 Open source Current Liabilities: 88466000 Open source
20182018-12-31	Current assets / current liabilities	3.31×	Current Assets: 267235000 Open source Current Liabilities: 80661000 Open source
20192019-12-31	Current assets / current liabilities	11.83×	Current Assets: 496905000 Open source Current Liabilities: 41998000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 83.22 million Exact value Exact value: -83217000 USD 2016-01-01 – 2016-12-31: -83217000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Akcea Therapeutics, Inc. · 2016-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Net Income: -83217000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83217000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459019005745/akca-20181231.xml#217851 Filing: 000156459019005745 The citation records this snapshot. The page link may show a newer release later.	−USD 55.36 million Exact value Exact value: -55361000 USD 2016-01-01 – 2016-12-31: -55361000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akcea Therapeutics, Inc. · 2016-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Operating Cash Flow: -55361000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55361000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459019005745/akca-20181231.xml#292866 Filing: 000156459019005745 The citation records this snapshot. The page link may show a newer release later.	USD 179,000 Exact value Exact value: 179000 USD 2016-01-01 – 2016-12-31: 179000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akcea Therapeutics, Inc. · 2016-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Capital Expenditure: 179000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 179000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459019005745/akca-20181231.xml#294872 Filing: 000156459019005745 The citation records this snapshot. The page link may show a newer release later.	−USD 55.54 million Calculation and evidence -55361000 − 179000 USD Exact free cash flow: -55540000 USD 2016-01-01 – 2016-12-31: -55361000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 179000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akcea Therapeutics, Inc. · 2016-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Free cash flow: -55540000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55361000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459019005745/akca-20181231.xml#292866 Filing: 000156459019005745 Input fundies:CapitalExpenditure: 179000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459019005745/akca-20181231.xml#294872 Filing: 000156459019005745 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 121.56 million Exact value Exact value: -121559000 USD 2017-01-01 – 2017-12-31: -121559000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Akcea Therapeutics, Inc. · 2017-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Net Income: -121559000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -121559000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#245984 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	−USD 36.19 million Exact value Exact value: -36190000 USD 2017-01-01 – 2017-12-31: -36190000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akcea Therapeutics, Inc. · 2017-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Operating Cash Flow: -36190000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36190000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#298191 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2017-01-01 – 2017-12-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akcea Therapeutics, Inc. · 2017-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#300202 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	−USD 36.2 million Calculation and evidence -36190000 − 9000 USD Exact free cash flow: -36199000 USD 2017-01-01 – 2017-12-31: -36190000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akcea Therapeutics, Inc. · 2017-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Free cash flow: -36199000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36190000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#298191 Filing: 000156459020008119 Input fundies:CapitalExpenditure: 9000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#300202 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 225.82 million Exact value Exact value: -225821000 USD 2018-01-01 – 2018-12-31: -225821000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Akcea Therapeutics, Inc. · 2018-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Net Income: -225821000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -225821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#245829 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	−USD 202.89 million Exact value Exact value: -202888000 USD 2018-01-01 – 2018-12-31: -202888000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akcea Therapeutics, Inc. · 2018-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Operating Cash Flow: -202888000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -202888000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297978 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	USD 1.12 million Exact value Exact value: 1119000 USD 2018-01-01 – 2018-12-31: 1119000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akcea Therapeutics, Inc. · 2018-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Capital Expenditure: 1119000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1119000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299992 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	−USD 204.01 million Calculation and evidence -202888000 − 1119000 USD Exact free cash flow: -204007000 USD 2018-01-01 – 2018-12-31: -202888000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1119000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akcea Therapeutics, Inc. · 2018-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Free cash flow: -204007000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -202888000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297978 Filing: 000156459020008119 Input fundies:CapitalExpenditure: 1119000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299992 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 40.77 million Exact value Exact value: 40772000 USD 2019-01-01 – 2019-12-31: 40772000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Net Income: 40772000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 40772000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#245676 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	USD 223.83 million Exact value Exact value: 223825000 USD 2019-01-01 – 2019-12-31: 223825000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Operating Cash Flow: 223825000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 223825000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297766 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	USD 1.6 million Exact value Exact value: 1596000 USD 2019-01-01 – 2019-12-31: 1596000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Capital Expenditure: 1596000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1596000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299782 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.	USD 222.23 million Calculation and evidence 223825000 − 1596000 USD Exact free cash flow: 222229000 USD 2019-01-01 – 2019-12-31: 223825000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1596000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akcea Therapeutics, Inc. · 2019-12-31 Akcea Therapeutics, Inc. (edgar:1662524) Free cash flow: 222229000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:07:35Z Snapshot: e6616585fe09405c57e1c63115a833b2a2663ee75fa0232bed8fbed58f5a73b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662524?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 223825000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#297766 Filing: 000156459020008119 Input fundies:CapitalExpenditure: 1596000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662524/000156459020008119/akca-20191231.xml#299782 Filing: 000156459020008119 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

64 filings · 1,308 latest values · 1,308 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001662524, 1662524, AKCA, edgar:1662524

Also known as AKCEA THERAPEUTICS, INC., Akcea Therapeutics, Inc.

Akcea Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation